Research Practice Sample Clauses

Research Practice. 3.1 The Institution and the Grantholder will at all times during the continuance of the Agreement comply with:
Sample 1Sample 2
AutoNDA by SimpleDocs
Research Practice. The Employing Institution must ensure that all the necessary legal and regulatory requirements in order to conduct the research are met and all the necessary licences and Ethical Committee approvals have been obtained. Where any part of the research is to be conducted outside the UK such legal and regulatory requirements, and such licences and approvals, should include those applicable in the additional countries involved. The Employing Institution must have in place formal written procedures for the handling of allegations of research misconduct and on request must make those available to Guts UK. The Xxxxx Xxxxxx or any other person working on the Grant Activities must carry out any animal research using the Grant in accordance with the appropriate Home Office licences and certificates which must remain valid. The Employing Institution must ensure that research involving animals gives due consideration to the refinement, reduction and replacement of animals in research and adheres to the principles in the NC3Rs “Responsibility in the Use of Animals in Bioscience Research”. Site visits may be made at any time subject to mutual agreement. Financial Control Payment of the Grant will not commence until the Grant Budget, including salary details if covered and a breakdown of consumable and other miscellaneous costs, has been confirmed by the Employing Institution's Administrative Officer in the Admin Officer Letter. Guts UK will not cover any expenditure not stated in the Grant Budget. Conference travel expenses and publication costs will only be covered if allowed by the grant application guidelines published by Guts UK for the type of the project funded by the Grant. The Grant Budget in the Admin Officer Letter cannot include any items of expenditure which are disallowed in the grant application guidelines published by Guts UK for the type of project funded by the Grant. Xxxxx instalments are paid to the Employing Institution quarterly, in arrears, subject to receipt by Guts UK of an invoice. Quarterly invoices must state the start and end dates of the period covered by the invoice and provide a breakdown of costs incurred against the items of expenditure in the Grant Budget. All invoices must be submitted within 6 months of the end of the Grant Period. Guts UK will not pay the final claim until it has received the Final Report (see term 6.2) and is satisfied that the Grant Activities have been delivered in accordance with the Award Letter and any Special C...
Sample 1Sample 2
Research Practice. The Xxxxx Xxxxxx must ensure that research under the Project is conducted in compliance with all applicable laws and regulations and that all necessary licences and approvals have been obtained.
Sample 1Sample 2
Research Practice. 3.1. The Lead Applicant Institution and Lead Applicant shall ensure the Research;
Sample 1Sample 2
Research Practice. The Institution and the Grantholder will at all times during the continuance of this Agreement comply with: the Policies; the terms of this Agreement; and any laws and regulations (as amended from time to time) applicable to the Project and this Agreement including human tissue legislation, health & safety legislation, the Data Protection Act 1998 and the Bribery Act 2010. It is a condition of the Grant that the research undertaken in connection with the Project is conducted in accordance with best scientific and ethical practice. The Institution warrants that it has in place, and will continue to have in place through the Grant Period, formal written policies setting out the standards to be met in the conduct of research and the procedures to be followed following any allegation of research misconduct. If at any time during or after the Grant Period, allegations of research misconduct are made in relation to the Grant, or in relation to the Grantholder in connection with any other research, and are, in the reasonable opinion of Diabetes UK, substantiated, Diabetes UK reserves the right to take such steps as it, at its absolute discretion, considers appropriate which may include (but is not limited to): Requiring the Institution to remove the Grantholder from the Project; Requiring the Institution and/or Grantholder to retract published material; withholding payment of subsequent instalments of the Grant, or requiring the Institution to reimburse Diabetes UK for some or all instalments of the Grant already paid; taking such steps as it considers necessary to monitor the subsequent conduct of the Project and the Institution and the Grantholder will co-operate with Diabetes UK to facilitate this; terminating the Grant with immediate effect. The Institution and the Grantholder will conduct the Project in accordance with the principles set out in the Concordat to Support Research Integrity policy (xxxx://xxx.xxxxxxxxxxxxxx.xx.xx/highereducation/Documents/2012/TheConcordatToSupportResearchIntegrity.pdf) The Grantholder and the Institution will comply with the terms of the policy on the use of animals in medical research (insert link to policy). Prior to the commencement of the Project, the Grantholder and the Institution will obtain any and all licences, consents and approvals (including ethical approval) necessary to the conduct of the Project, will continue to hold such licences, consents and approvals during the Grant Period, and will promptly upon request p...
Sample 1

Related to Research Practice

  • Research Project 3.1 These Materials and Data will be used by Recipient's PI solely in connection with the Research Project, as named and described in the attached research application (insert Research Project name below):

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Development cooperation 1. The Parties recognise that development cooperation is a crucial element of their Partnership and an essential factor in the realisation of the objectives of this Agreement as laid down in Article 1. This cooperation can take financial and non-financial forms.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Time is Money Join Law Insider Premium to draft better contracts faster.